PCSK9 Ligand Design for Personalized Cholesterol Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current medical treatments for PCSK9-mediated diseases lack personalized approaches, leading to inefficiencies in diagnosis and therapy due to genetic variations among individuals, resulting in suboptimal treatment outcomes and medication wastage.
Innovation Solution
The development of tailored anti-PCSK9 ligands and antibodies that specifically target varying forms of the PCSK9 protein based on individual genetic profiles, allowing for personalized medicine approaches that match the ligand to the patient's genetic or phenotypic makeup.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If a single standardized PCSK9 treatment is used for all patients, then manufacturing and administration are simplified, but treatment efficacy is reduced due to genetic variations among individuals
Solution Approach 1:
The invention segments the patient population based on genetic variations in PCSK9 gene sequences. Different patient groups are identified with specific genetic profiles (e.g., presence of particular SNPs or mutations), and each group is matched with appropriately designed anti-PCSK9 ligands that target their specific genetic variants, thereby resolving the contradiction between standardized treatment and personalized efficacy
Solution Approach 2:
The invention applies local quality by designing anti-PCSK9 ligands with specific binding characteristics tailored to match particular PCSK9 genetic variants. Each ligand is optimized to recognize and bind to the specific amino acid sequence variations present in different patient populations, ensuring high treatment efficacy for each genetic subgroup while maintaining a systematic approach to patient classification
2Reliability
If personalized anti-PCSK9 ligands are developed for different genetic profiles, then treatment efficacy is improved, but device and treatment complexity increases
Solution Approach 1:
The invention implements preliminary action by performing genetic testing and profiling of patients before treatment initiation. Patients are pre-classified into genetic groups based on their PCSK9 gene sequences, and appropriate ligands are selected in advance based on this pre-determined genetic classification, simplifying the overall treatment process despite the personalized nature of the therapy
Solution Approach 2:
The invention applies universality by developing a multi-functional diagnostic and treatment system that combines genetic testing, patient classification, and ligand selection into an integrated framework. The system can handle multiple genetic variants and corresponding ligands through a unified approach, reducing the perceived complexity by providing a comprehensive solution rather than separate components
3Measurement precision
If genetic testing and profiling are performed on all patients, then personalized treatment matching is achieved, but loss of time in diagnosis and treatment initiation increases
Solution Approach 1:
The invention applies partial action by implementing a tiered genetic testing strategy. Not all patients undergo complete genomic sequencing; instead, targeted testing for specific known PCSK9 variants or hotspots is performed based on clinical presentation and risk factors. This approach achieves sufficient measurement precision for treatment matching while significantly reducing the time required compared to comprehensive genomic analysis
Data Source
AI summary
The invention relates to human targets of interest (TOI), anti-TOI ligands, kits compositions and method.